Myeloproliferative neoplasms
JL Spivak - New England Journal of Medicine, 2017 - Mass Medical Soc
JL Spivak
New England Journal of Medicine, 2017•Mass Medical SocMyeloproliferative Neoplasms | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge,
lead a health care organization, and advance your career with NEJM Group information and
services. NEJM Evidence NEW! A digital journal for innovative original research and fresh,
bold ideas in clinical trial design and clinical decision-making. NEJM Catalyst NEW!
Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care …
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge,
lead a health care organization, and advance your career with NEJM Group information and
services. NEJM Evidence NEW! A digital journal for innovative original research and fresh,
bold ideas in clinical trial design and clinical decision-making. NEJM Catalyst NEW!
Peer-reviewed journal featuring in-depth articles to accelerate the transformation of health care …
The myeloproliferative disorders, comprising polycythemia vera, essential thrombocytosis, and myelofibrosis, are clonal hematopoietic cancers that have an indolent course. The clinical manifestations of these entities overlap, as do their genetic drivers.
The New England Journal Of Medicine